SEC Filing Summary: Hemispherx Biopharma, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Hemispherx Biopharma, Inc. on April 12, 2006. The filing discloses the entry into a material definitive agreement and the unregistered sale of equity securities. The company is incorporated in Delaware and headquartered in Philadelphia, Pennsylvania.
Key Financial Metrics and Transaction Details
- Financing Agreement: Entered into a Common Stock Purchase Agreement with Fusion Capital Fund II, LLC.
- Total Commitment: Up to $50,000,000 of common stock to be purchased over approximately 25 months.
- Initial Issuance: 321,751 shares of common stock issued immediately upon signing.
- Pricing Mechanism: Future shares will be sold at the lower of the day's lowest trade price or the average of the three lowest closing prices from the preceding 12 trading days.
- Daily Cap: The Company has the right to sell up to $100,000 of stock per trading day once the registration statement is effective.
- Use of Proceeds: General corporate purposes.
- Financial Statements: The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period.
Material Changes
The primary material change is the establishment of a new financing facility with Fusion Capital. This agreement provides a mechanism for the Company to raise capital over the next 25 months, subject to market pricing conditions. The initial issuance of 321,751 shares was made pursuant to an exemption from registration under Section 4(2) of the Securities Act of 1933.
Outlook, Risks, and Management Commentary
- Registration Rights: The Company agreed to file a registration statement with the SEC by June 30, 2006, covering shares issued under the agreement.
- Flexibility: Under certain conditions, the Company may require Fusion Capital to purchase greater amounts of stock than the standard daily cap.
- Risks: The pricing formula ties the purchase price to the lowest recent trading prices, which could result in significant dilution if the stock price declines. The filing does not explicitly list other risks or contingencies beyond the terms of the agreement.
Key Facts for Investor Verification
- Verify the effectiveness date of the Registration Statement to be filed by June 30, 2006.
- Monitor the Company's stock price volatility, as the purchase price is based on the lowest trade prices, potentially accelerating dilution during downturns.
- Confirm the actual amount of capital raised versus the $50,000,000 commitment over the 25-month term.
- Review the specific "certain conditions" under which the Company can require increased purchase amounts from Fusion Capital.